Stock analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the stock.
Navidea Biopharmaceuticals Price Performance
Shares of NAVB stock opened at $0.00 on Tuesday. Navidea Biopharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.13. The company has a market capitalization of $100,084.00, a P/E ratio of -0.02 and a beta of 1.46.
About Navidea Biopharmaceuticals
Featured Articles
- Five stocks we like better than Navidea Biopharmaceuticals
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Why is the Ex-Dividend Date Significant to Investors?
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.